SCHEMBL20060971

SCHEMBL20060971

CN(C)C(=O)c1ccc(OC2CCC3(CC2)CCN(C(=O)OC(C)(C)C)CC3)nc1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 10/20 0.61
NR1H2 P55055 1/20 0.40
NR1H3 Q13133 1/20 0.40
POLB P06746 1/20 0.39
KDM1A O60341 1/20 0.39
CYP11B2 P19099 1/20 0.38
CACNB4 O00305 2/20 0.38
CACNA1A O00555 2/20 0.38
CACNA1G O43497 2/20 0.38
CACNG3 O60359 2/20 0.38
CACNA1F O60840 2/20 0.38
CACNA1H O95180 2/20 0.38
CACNB3 P54284 2/20 0.38
CACNA2D1 P54289 2/20 0.38
CACNG7 P62955 2/20 0.38
CACNA1B Q00975 2/20 0.38
CACNA1D Q01668 2/20 0.38
CACNB1 Q02641 2/20 0.38
CACNG1 Q06432 2/20 0.38
CACNB2 Q08289 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20060975 0.90 GPR119 (0.76) GPR119KDM1ACYP11B2NAMPT
SCHEMBL22311046 0.77 GPR119 (0.37) GPR119NR1H2NR1H3CACNB4CACNA1A
SCHEMBL2554482 0.76 GPR119 (1.00) GPR119KDM1ANPBWR1MCHR1
SCHEMBL12283198 0.76 GPR119 (1.00) GPR119KDM1ANPBWR1MCHR1
SCHEMBL22284269 0.76 GPR119 (0.55) GPR119NAMPT
SCHEMBL20061052 0.76 GPR119 (0.62) GPR119NR1H2NR1H3POLB
SCHEMBL22311044 0.75 NR1H2 (0.44) GPR119NR1H2NR1H3CACNB4CACNA1A
SCHEMBL22311043 0.75 NR1H2 (0.44) GPR119NR1H2NR1H3CACNB4CACNA1A
SCHEMBL30451141 0.75 NR1H2 (0.44) GPR119NR1H2NR1H3CACNB4CACNA1A
SCHEMBL26631360 0.75 GPR119 (0.42) GPR119CYP11B2CACNB4CACNA1ACACNA1G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3526196-B1 ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS MERCK SHARP & DOHME LLC (US) 2026-03-18 EP disclosed
US-11655216-B2 Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use MERCK SHARP & DOHME LLC (US) 2023-05-23 US disclosed
US-11655216-B2 Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use MERCK SHARP & DOHME LLC (US) 2023-05-23 US disclosed
US-20200247754-A1 ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2020-08-06 US disclosed
WO-2018068295-A1 ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2018-04-19 WO disclosed
WO-2018071317-A1 ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS MERCK SHARP & DOHME CORP. (US) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247754-A1 ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE NR1H2, NR1H3, NR1H4 GPR119 15/4885NR1H2 1/4885NR1H3 2/4885
US-11655216-B2 Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use NR1H2, NR1H3, NR1H4 GPR119 15/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.